ArticleWorld journal of oncology2025
Metabolic Reprogramming-Related Genes in Lung Adenocarcinoma: Identification and Prognostic Model Construction.
Article in World journal of oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical phenotype identification based on inflammation-nutrition-coagulation biomarkers in advanced non-small cell lung cancer.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung adenocarcinoma (LUAD), the predominant histological subtype of lung cancer, persists in presenting a dismally low 5-year overall survival (OS) rate, notwithstanding advancements in treatment modalities. There exists a pressing necessity for the identification of innovative biomarkers that can enhance prognostic assessments and facilitate individualized therapeutic strategies. The objective of this investigation was to clarify the involvement of genes associated with metabolic reprogramming in the progression of LUAD and to evaluate their viability as prognostic indicators. Methods: An analysis of differential gene expression was performed utilizing The Cancer Genome Atlas (TCGA)-LUAD dataset, supplemented by a weighted gene co-expression network analysis (WGCNA). Through intersection analysis focusing on metabolic reprogramming genes (MRGs), pivotal differentially expressed metabolic reprogramming genes (hub DEMRGs) were identified. Consensus clustering categorized patients into subtypes based on these genes. Functional enrichment analysis and immune microenvironment characterization were conducted, followed by Cox and least absolute shrinkage and selection operator (LASSO) regression analyses to construct a prognostic risk model. Results: A total of 31 hub DEMRGs were identified. Patients were classified into two distinct subtypes (C1 and C2), with the C2 subtype exhibiting a markedly reduced OS rate. Functional enrichment revealed significant activation of nuclear division and cell cycle pathways in C2. Immune profiling demonstrated an immunosuppressive phenotype in C2, characterized by elevated M2 macrophage infiltration and reduced CD8 Conclusions: This research highlights the critical role of MRGs in LUAD prognosis and their potential for clinical application. The identified subtypes and risk model provide insights into tumor heterogeneity and immunosuppressive mechanisms, offering potential targets for individualized therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.